Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Cardiology in pregnancy

Cardiology in pregnancy examines adaptations of the maternal cardiovascular system and the prevention, recognition and treatment of heart and vascular diseases during the preconception period, pregnancy, childbirth and the puerperium. Its clinical scope includes both women with previously known heart disease and patients in whom a disorder is identified for the first time during pregnancy. Assessment must integrate maternal health, uteroplacental perfusion, fetal development and the effects of treatments through a care pathway in which cardiology, maternal–fetal medicine and obstetric anesthesia share decisions.

Cardiovascular diseases are among the leading causes of maternal mortality in high-income countries. Their burden reflects the survival into reproductive age of a growing number of women with congenital heart disease, increasing maternal age and the greater prevalence of hypertension, obesity and diabetes. Frequency estimates vary substantially according to the disorders included: hypertensive disorders affect a far larger population than structural heart diseases alone. This distinction is essential when interpreting data, because a registry of women with heart disease describes risk in a selected population, not across all pregnancies.

Pregnancy causes a physiological increase in cardiac workload and tests cardiovascular reserve. A healthy heart accommodates these changes while maintaining adequate perfusion; a stenotic valve, a dysfunctional ventricle or a pulmonary circulation with high vascular resistance may instead become symptomatic. Alongside pre-existing conditions, disorders associated with the reproductive period may develop, including peripartum cardiomyopathy and preeclampsia. Understanding the physiology makes it possible to recognize when a symptom exceeds the expected adaptation and requires prompt assessment.

Cardiovascular adaptations and pathophysiological mechanisms

In the first weeks, systemic vasodilation develops, driven in part by hormonal changes, increased nitric oxide availability and changes in vascular reactivity. The reduction in resistance precedes the full development of placental circulation: the new uteroplacental vascular bed subsequently helps maintain a low-resistance system. Blood pressure tends to decrease during the first part of pregnancy, particularly its diastolic component, then rises toward pre-pregnancy levels near term. The individual trajectory also depends on pre-existing blood pressure, body composition and clinical conditions.

Vasodilation reduces effective arterial filling, activating mechanisms that conserve sodium and water. Increased activity of the renin–angiotensin–aldosterone system, together with changes in osmotic regulation, supports plasma volume expansion. In physiological pregnancy, the vasoconstrictor response to angiotensin II is attenuated, so hormonal activation can coexist with low vascular resistance. Red cell mass also increases, but less than plasma volume: the resulting hemodilution lowers hemoglobin concentration. This physiological reduction does not justify overlooking iron deficiency, which must be identified through appropriate investigations.

Expansion of circulating volume and increased heart rate raise cardiac output, generally by approximately 30–50% relative to the pre-pregnancy state, with variations according to gestational age and measurement method. Early on, the increase in stroke volume contributes most; later, heart rate becomes more important. The left ventricle therefore faces predominantly volume overload with reduced afterload. Cardiac chambers may enlarge moderately and myocardial mass may increase, while ejection fraction normally remains preserved.
Physiological remodeling affects the entire heart in a coordinated manner. Marked dilatation, new ventricular dysfunction or a substantial increase in filling pressures require a pathological explanation; pregnancy alone does not account for these findings.

Increased blood flow changes how Doppler echocardiography is interpreted. Velocities across a normal valve or a well-functioning prosthesis may increase because of higher output, while small functional regurgitant jets may become more evident. Assessment of valvular disease severity must integrate anatomy, flow-independent parameters and comparison with previous studies. Ventricular trabeculations may also become transiently more prominent: echocardiographic morphology alone, without dysfunction, family history or other clinical features, is insufficient to establish cardiomyopathy.

As the uterus enlarges, aortocaval compression becomes relevant. In the supine position, compression of the inferior vena cava can reduce venous return, cardiac output and blood pressure, causing nausea, malaise or presyncope; the left lateral position tends to improve hemodynamics. Body position therefore influences symptoms and some clinical measurements. This phenomenon is particularly important during procedures, anesthesia and resuscitation, when impaired venous return can aggravate existing cardiovascular compromise.

Pregnancy also changes hemostasis. Increases in several coagulation factors, reduced protein S and changes in fibrinolysis promote a prothrombotic state, accompanied by venous stasis and, during delivery, tissue injury. This adaptation limits blood loss when the placenta separates, but increases the likelihood of thrombosis in predisposed patients. Immobility, obesity, previous thromboembolism and certain thrombophilias further increase risk; the puerperium is particularly vulnerable. Venous thromboembolism in pregnancy results from the interaction of these factors, not from any single laboratory abnormality.

During labor, pain, contractions and sympathetic activation further increase cardiac workload. After delivery, uterine contraction, relief of vena caval compression and fluid redistribution may rapidly increase venous return, while the low-resistance placental vascular bed disappears. These changes explain why the early puerperium can precipitate pulmonary edema or ventricular failure in a woman who tolerated pregnancy. The return to the previous physiological state is gradual, and different hemodynamic, structural and hemostatic parameters do not all normalize simultaneously.

Etiology of pathological conditions and risk factors

Pregnancy and cardiovascular disease interact through different pathways. In pre-existing congenital heart defects, valvular diseases and cardiomyopathies, the demands of pregnancy may exceed the compensatory capacity of an anatomical or functional lesion. In other cases pregnancy reveals a previously silent predisposition, such as genetically determined cardiomyopathy or inherited aortopathy. Finally, there are syndromes in which the placenta, vascular changes and peripartum period contribute directly to pathogenesis. Assessment of cardiovascular diseases in pregnancy must reconstruct this relationship to select monitoring and treatment appropriate to the underlying mechanism.

Lesions that obstruct blood flow are particularly sensitive to increased cardiac output. In mitral stenosis, increased circulating volume and shorter diastole raise left atrial pressure and pulmonary congestion. In severe aortic stenosis, the ventricle may have a limited ability to increase output. Pre-existing systolic dysfunction instead reduces contractile reserve; marked diastolic dysfunction can raise filling pressures even with a normal ejection fraction. In pulmonary arterial hypertension, the right ventricle faces elevated afterload and may fail when greater blood flow is required.

Hypertensive disorders encompass conditions with different courses and implications. Chronic hypertension predates pregnancy or is generally recognized before 20 weeks; gestational hypertension develops after that time without the features defining preeclampsia. Depending on the definition used, preeclampsia involves hypertension accompanied by maternal organ and/or uteroplacental dysfunction and can occur even without proteinuria. Abnormal placental adaptation, angiogenic imbalance and endothelial dysfunction contribute to multisystem involvement requiring coordinated evaluation by obstetrics and internal medicine.

Older maternal age, obesity, diabetes, kidney disease, previous preeclampsia and multiple pregnancy modify the risk profile but do not automatically indicate heart disease. In women with known heart disease, systemic ventricular function, functional class, cyanosis, pulmonary pressures, severity of obstruction and history of heart failure or arrhythmias are particularly relevant. Timely access to care, availability of medication and the ability to undergo follow-up also contribute to outcomes: differences between populations must not be reduced to exclusively biological explanations.

Clinical manifestations: from history-taking to physical examination

History-taking begins by establishing when symptoms occurred in relation to conception, pregnancy progression and delivery. Mild exertional dyspnea, awareness of the heartbeat and symmetrical dependent edema may accompany normal pregnancy; they have different implications if they appear suddenly, worsen markedly or restrict activities previously well tolerated. It is important to determine whether breathlessness occurs at rest or when lying down, wakes the patient from sleep or accompanies coughing, chest pain, prolonged palpitations or rapid weight gain. Orthopnea and paroxysmal nocturnal dyspnea require particular attention because they suggest cardiac congestion.

Chest pain must be characterized by onset, duration, radiation and its relationship to exertion, breathing and position. Persistent pressure, sudden very severe pain or pain accompanied by syncope, dyspnea or neurological deficits call for urgent assessment. Among ischemic syndromes in pregnancy, spontaneous coronary artery dissection is particularly important and can affect women without traditional atherosclerotic risk factors. Acute chest or back pain in a woman with aortopathy, by contrast, requires immediate consideration of aortic dissection.

When assessing palpitations, the onset and end of episodes, rhythm regularity, duration, frequency and associated symptoms are established. Brief episodes of ectopic beats are common, whereas sustained tachycardia, loss of consciousness or a family history of sudden death warrant further investigation. The history must include childhood heart disease, operations, prosthetic heart valves, previous thrombosis, treatments, cardiotoxic exposures and outcomes of previous pregnancies. In women with congenital heart disease, the residual physiology after surgery is important, because anatomical correction does not necessarily mean full normalization of function.

Physical examination begins with general condition, respiratory rate, oxygen saturation, blood pressure and heart rate. Blood pressure should be measured with an appropriately sized cuff and a device validated for pregnancy, with repeat readings in the appropriate setting; severely elevated values require rapid confirmation. Assessment then includes peripheral perfusion, pulses, jugular veins, cardiopulmonary auscultation and signs of edema or limb asymmetry. An increased-flow systolic murmur may be physiological; a diastolic murmur, cyanosis, persistent crackles or signs of venous congestion require a clinical and instrumental explanation.

The urgency of care depends on the combined findings. Persistent chest pain, oxygen desaturation, hypotension, altered mental status, exertional syncope, neurological deficits and breathlessness at rest are situations in which investigations and stabilization must proceed together. Severe headache, visual disturbances and epigastric or right upper quadrant pain, especially with hypertension, also point toward hypertensive obstetric complications. Cardiological assessment must encompass these possibilities and remain coordinated with the obstetric team.

Investigations, diagnosis and risk stratification

No single test diagnoses a generic “pregnancy-related heart disease.” Assessment first addresses the clinical question raised by the examination, then defines the lesion, its severity and its maternal–fetal consequences. An electrocardiogram documents rhythm, conduction and possible signs of injury or overload; some axis and repolarization changes may accompany pregnancy, but suspected ischemia or significant arrhythmia requires specific interpretation. Blood tests are selected to identify anemia, electrolyte abnormalities, renal or thyroid dysfunction and, when needed, myocardial injury or hypertensive complications.

Transthoracic echocardiography is the primary test for evaluating cardiac structure and function: it examines both ventricles, valves, the proximal aorta, pericardium and hemodynamic estimates. It is indicated for suspicious symptoms or findings and for surveillance of known heart disease; it is not automatically a universal screening test for every healthy pregnant woman. Interpretation must account for loading conditions, avoiding overestimation of stenosis severity based solely on a higher gradient or mistaking genuine dysfunction for a physiological adaptation.

Natriuretic peptides help assess possible heart failure. Low values make heart failure less likely, whereas elevated levels must be interpreted alongside examination and echocardiography; obesity, kidney function and the immediate postpartum period may affect interpretation. Troponin documents myocardial injury and is measured when there is an appropriate clinical indication, particularly chest pain or instability. An elevated value should not automatically be attributed to pregnancy, nor does it alone establish infarction: diagnosis of myocardial infarction also requires evidence of ischemia.

Second-line investigations are selected to answer a specific question. Ambulatory electrocardiographic monitoring correlates symptoms with rhythm; magnetic resonance imaging without gadolinium can clarify anatomy and function when echocardiography is insufficient. CT, scintigraphy and angiography remain available when needed to identify or treat urgent conditions. Pregnancy calls for dose optimization and benefit assessment, but should not delay a life-saving diagnosis. For example, a normal echocardiogram alone does not exclude pulmonary embolism, coronary syndrome or disease of the entire aorta.

Risk assessment in women with heart disease uses the mWHO 2.0 classification proposed by the 2025 ESC guidelines, alongside individual characteristics and validated models such as CARPREG II. The classification organizes maternal risk and the required level of care; it does not replace diagnosis. Functional class, ventricular function, prior events and the nature of the lesion remain central. Fetal risk is assessed separately through obstetric history, maternal perfusion and oxygenation, drug exposure and, when indicated, genetic counseling and fetal echocardiography.

Prevention, treatment and organization of care

The most effective prevention begins with preconception counseling. For women with cardiovascular disease, clinical stability, cardiac function, aortic anatomy where relevant, need for interventions and treatment compatibility with conception must be assessed. Counseling covers the likelihood of adverse events, possible fetal effects, reproductive alternatives and the patient's preferences. Very-high-risk conditions require an explicit, individualized discussion; if pregnancy has already begun, assessment must be prompt and conducted by professionals with specific experience.

The Pregnancy Heart Team brings together a cardiologist, an obstetrician specializing in maternal–fetal medicine and an anesthesiologist, involving other specialists, a neonatologist and a geneticist as needed. The care plan determines the frequency of assessments, place of delivery, monitoring, medication management and how to access care if the condition worsens. In higher-risk situations, it is essential to make decisions before an emergency arises, especially when catheter-based interventions, cardiac surgery or circulatory support may be necessary.

Drug treatment is based on balancing maternal benefits against fetal exposure, taking gestational age, dosage and duration into account. Medications within the same class are not interchangeable, and compatibility with pregnancy differs from compatibility with breastfeeding. ACE inhibitors, angiotensin receptor blockers and sacubitril/valsartan require replacement during pregnancy; certain beta-blockers, diuretics when needed and selected vasodilators may instead have an essential role. Changes in renal filtration, volume of distribution and protein binding can alter drug exposure and make closer monitoring necessary.

Controlling hypertension reduces maternal complications and is achieved with medications appropriate for pregnancy. The CHAP trial showed that treating mild chronic hypertension to a target below 140/90 mmHg improves the composite outcomes studied without significantly increasing the proportion of infants who are small for gestational age. This finding concerns a defined population and must be considered together with the obstetric diagnosis and applicable recommendations. Prevention of preeclampsia with low-dose aspirin is reserved for women meeting the specified risk criteria, with timing and dosage determined by the protocol used.

Thromboembolism prevention requires repeated assessment because hospitalization, immobility, cesarean delivery and bleeding can modify risk during pregnancy and after delivery. When indicated, low-molecular-weight heparin is commonly used; however, women with mechanical prosthetic valves need a specific anticoagulation strategy distinct from obstetric prophylaxis. For arrhythmias in pregnancy, the choice between observation, medication, cardioversion and procedures depends on the documented rhythm, underlying heart disease and hemodynamic stability.

Mode of delivery depends on the obstetric and cardiovascular situation. In many stable heart conditions, vaginal delivery with adequate analgesia and careful fluid management offers advantages over routine cesarean delivery. Cesarean delivery is appropriate for obstetric indications and specific cardiac conditions, including certain forms of instability or high-risk aortopathy. Anesthesia, anticoagulation and uterotonics must be planned together: abrupt changes in vascular resistance, tachycardia and fluid overload may be poorly tolerated. Surveillance continues through the puerperium for a duration proportionate to the lesion and clinical course.

Complications, prognosis and future cardiovascular health

The most important maternal complications include heart failure, sustained arrhythmias, thromboembolism, ischemic events, acute aortic syndromes and hypertensive complications. The mechanism varies with the heart condition: obstruction to filling may cause congestion; ventricular dysfunction may reduce cardiac output; a mechanical prosthesis may thrombose if anticoagulation is inadequate. Prognosis therefore cannot be inferred from the label “heart disease in pregnancy” alone but requires assessment of the lesion, functional reserve and available treatments.

Fetal consequences may result from uteroplacental hypoperfusion, maternal hypoxemia, placental disease or the need for early delivery. Growth restriction, prematurity and fetal loss are more likely in severe maternal conditions, whereas many women with well-compensated heart disease have favorable outcomes. The probability of transmitting an inherited disorder is distinct from hemodynamic consequences and should be addressed through genetic counseling when indicated.

Postpartum discharge is one stage of care, not its endpoint. Blood pressure, symptoms, treatment and follow-up instructions must be reassessed, with clear continuity between obstetric and cardiological care. Breastfeeding is supported through the choice of compatible medications when circumstances allow; in severe conditions, maternal treatment needs may require different decisions, discussed with the patient. Contraception must be tailored to thrombotic risk, cardiac function and reproductive preferences to prevent unplanned exposure to medications incompatible with another pregnancy.

A history of preeclampsia, other hypertensive disorders, gestational diabetes or preterm delivery identifies an opportunity for long-term cardiovascular prevention. The association with later hypertension and cardiovascular disease reflects both pre-existing determinants and possible consequences of the pregnancy complication; it does not mean that every woman will develop heart disease. Blood pressure monitoring, metabolic assessment, appropriate physical activity, a balanced diet and ongoing care enable intervention on modifiable risk factors. Reproductive history thus becomes a permanent part of a woman's cardiovascular history.

Bibliography
  1. De Backer J et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. European Heart Journal. 2025;46(43):4462-4568.
  2. Sanghavi M et al. Cardiovascular physiology of pregnancy. Circulation. 2014;130(12):1003-1008.
  3. Meah VL et al. Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses. Heart. 2016;102(7):518-526.
  4. Mehta LS et al. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association. Circulation. 2020;141(23):e884-e903.
  5. Ramlakhan KP et al. Pregnancy and cardiovascular disease. Nature Reviews Cardiology. 2020;17(11):718-731.
  6. Curtis SL et al. Transthoracic Echocardiographic Assessment of the Heart in Pregnancy-a position statement on behalf of the British Society of Echocardiography and the United Kingdom Maternal Cardiology Society. Echo Research & Practice. 2023;10(1):7.
  7. Silversides CK et al. Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study. Journal of the American College of Cardiology. 2018;71(21):2419-2430.
  8. Roos-Hesselink J et al. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). European Heart Journal. 2019;40(47):3848-3855.
  9. Sarma AA et al. The Utilization and Interpretation of Cardiac Biomarkers During Pregnancy: JACC: Advances Expert Panel. JACC: Advances. 2022;1(3):100064.
  10. Magee LA et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension. 2022;27:148-169.
  11. Tita AT et al. Treatment for Mild Chronic Hypertension during Pregnancy. New England Journal of Medicine. 2022;386(19):1781-1792.
  12. Bates SM et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances. 2018;2(22):3317-3359.
  13. Joglar JA et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. 2023;20(10):e175-e264.
  14. Lewey J et al. Opportunities in the Postpartum Period to Reduce Cardiovascular Disease Risk After Adverse Pregnancy Outcomes: A Scientific Statement From the American Heart Association. Circulation. 2024;149(7):e330-e346.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.